Canadian Trade Boards Call For Drug Patents

31 March 1996

The Boards of Trade of Metropolitan Toronto and Metropolitan Montreal, where over 80% of Canadian drug industry jobs are situated, say that while Canada has improved its patent protection for medicines, "it has not attained the international standards established by most of its major competitors in the industrialized world."

For Canada to attract more research and job opportunities, participate more fully in the discovery and development of innovative drug therapies and win international manufacturing contracts, the Boards are calling for: intellectual property protection to be maintained and even reinforced; government continues to support business research programs; top-quality training of researchers and other drug industry workers; and recognition by provincial governments of the trade-offs between medications and health budget savings, and the increased economic activity generated by knowledge-based industries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight